A solidly profitable company with $446 million on top of $3.2 billion in revenue for the first nine months of 2012, Zoetis is poised to enjoy the largest stock market debut since Facebook's offering last spring. Zoetis raised $2.2 billion in its IPO.
The shares began trading 1 February 2013 on the NYSE under the symbol "ZTS" and were a hit among investors as shares jumped nearly 20% from their initial price of $26 to $31.01.
About Zoetis:
Formed six decades ago as the animal health business of Pfizer, Zoetis focuses on manufacturing and selling medicines for livestock and pets and is a leading animal health company, dedicated to supporting its customers and their businesses. The company generated annual revenue of $4.2 billion in fiscal 2011. Zoetis has more than 9,500 employees and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Zoetis filed with U.S. regulators for an IPO of Class A common stock August 2012 and completion was set for January 2013. Pfiser spun off Zoetis as part of its strategic plan to shed entities outside its core medicine business.
